| Title |
Complement inhibition in C3 glomerulopathy
|
|---|---|
| Published in |
Seminars in Immunology, July 2016
|
| DOI | 10.1016/j.smim.2016.06.002 |
| Pubmed ID | |
| Authors | |
| Abstract |
C3 glomerulopathy (C3G) describes a spectrum of glomerular diseases defined by shared renal biopsy pathology: a predominance of C3 deposition on immunofluorescence with electron microscopy permitting disease sub-classification. Complement dysregulation underlies the observed pathology, a causal relationship that is supported by well described studies of genetic and acquired drivers of disease. In this article, we provide an overview of the features of C3G, including a discussion of disease definition and a review of the causal role of complement. We discuss molecular markers of disease and how biomarkers are informing our evolving understanding of underlying pathology. Research advances are laying the foundation for complement inhibition as a targeted approach to treatment of C3G. |
Login to access the Attention Digest and the Sentiment Analysis related to this output.
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 56 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 9 | 16% |
| Researcher | 7 | 13% |
| Student > Ph. D. Student | 5 | 9% |
| Student > Master | 5 | 9% |
| Student > Doctoral Student | 3 | 5% |
| Other | 8 | 14% |
| Unknown | 19 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 34% |
| Biochemistry, Genetics and Molecular Biology | 5 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 7% |
| Immunology and Microbiology | 3 | 5% |
| Nursing and Health Professions | 2 | 4% |
| Other | 4 | 7% |
| Unknown | 19 | 34% |